This study is testing a new way to detect bladder cancer (BCa) non-invasively. Researchers are evaluating a multiplex ELISA assay, which is a type of lab test, using urine samples from people who have microscopic hematuria (blood in the urine that can only be seen under a microscope). The goal is to see if this new test can accurately identify bladder cancer, which is currently often missed by other urine tests. The study aims to enroll about 900 participants aged 18 to 90 years old who have had microscopic hematuria within the last three months and are willing to give their consent. Success will be measured by how well the test's sensitivity and specificity (its ability to correctly identify those with and without bladder cancer) are confirmed by a cystoscopy (an invasive procedure where a camera is inserted into the bladder) after one year. The current recruitment status is unclear.

Study design

This is an observational study, meaning researchers will observe and collect data without providing any specific intervention. It aims to enroll approximately 900 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, which measures the test's accuracy, will be assessed at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.